Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

The pharmaceutical company has received tentative approval from the USFDA to manufacture Enzalutamide tablets in 40 mg and 80 ...

Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Indian equity markets experienced their most significant weekly decline since June 2022, with both the Sensex and Nifty extending their losing streak for the fourth consecutive session on Friday, ...